Clinical Trials

LymphoidOther hematologic neoplasm

80 enrolled

Hodgkin Disease, Lymphoma, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large B-Cell, Diffuse

NCT03460977 2026-04-16

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

453 enrolled

LymphoidThoracic

Lymphoma, Follicular, Recurrence, Small Cell Lung Carcinoma

NCT03618550 2026-04-16

Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

257 enrolled

Lymphoid

Hodgkin Disease, Recurrence

NCT03866382 2026-04-16

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

314 enrolled

Genitourinary

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Penile Neoplasms, Prostatic Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

NCT03922555 2026-04-16

ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas

18 enrolled

Central Nervous System Neoplasms

NCT03934372 2026-04-16

Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors

LymphoidOther hematologic neoplasm

70 enrolled

Blast Crisis, Leukemia, Lymphoma, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04003038 2026-04-16

Negative Pressure Wound Therapy in Healing Abdominal Incision in Obese Patients Undergoing Breast Reconstruction Surgery

80 enrolled

BreastOther

Breast Neoplasms, Obesity

NCT04140487 2026-04-16

Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm

MyeloidOther hematologic neoplasm

97 enrolled

Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases

NCT04237623 2026-04-16

GM-CSF With Post-Transplant Cyclophosphamide

38 enrolled

Transplant-Related Hematologic Malignancy

NCT04316546 2026-04-16

MK-7075 (Miransertib) in Proteus Syndrome

45 enrolled

Proteus Syndrome

NCT04493138 2026-04-16

Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations

MyeloidOther hematologic neoplasm

58 enrolled

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic

NCT04521231 2026-04-16

A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL

LymphoidOther hematologic neoplasm

281 enrolled

Recurrence, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04595422 2026-04-16

Educating Smokers About Lung Cancer Screening Using Tobacco Quitlines

800 enrolled

Lung Neoplasms

NCT04606446 2026-04-16

KAT6

320 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04615013 2026-04-16

NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer

GastrointestinalGynecologic

24 enrolled

Cervical Esophagus Adenocarcinoma

NCT04665739 2026-04-16

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

70 enrolled

EndocrineNET

Advanced Lung Neuroendocrine Tumor

NCT04671667 2026-04-16

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

188 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04701476 2026-04-16

TATE and Pembrolizumab (MK3475) in mCRC and NSCLC

110 enrolled

GastrointestinalThoracic

Lung Neoplasms, Colorectal Neoplasms

NCT04783168 2026-04-16

AIRTECH

240 enrolled

Lung Neoplasms

NCT04789681 2026-04-16

Canakinumab for the Prevention of Lung Cancer, the Can-Prevent-Lung Trial

50 enrolled

Lung Neoplasms

NCT04796012 2026-04-16

VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors

23 enrolled

Sarcoma

Rhabdomyosarcoma

NCT04829539 2026-04-16

Comparing Brief Behavioral Therapy (BBT-CI) and Healthy Eating Education Learning (HEAL) for Cancer-Related Sleep Problems While Receiving Cancer Treatment

400 enrolled

Hematologic Neoplasms

NCT04879121 2026-04-16

Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors

13 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT04973605 2026-04-16

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

246 enrolled

Plasma cell

Multiple Myeloma

NCT05013892 2026-04-16

NTS-WBRT in Brain Metastases

41 enrolled

Brain Neoplasms

NCT05026983 2026-04-16

Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases

35 enrolled

Dermatologic

Melanoma

NCT05064280 2026-04-16

Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases

104 enrolled

Brain Neoplasms, Neoplasms

NCT05101213 2026-04-16

Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients

30 enrolled

Adenoviridae Infections, Cytomegalovirus Infections, Hematologic Neoplasms

NCT05123807 2026-04-16

Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)

30 enrolled

Gynecologic

Ovarian Neoplasms

NCT05256225 2026-04-16

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

360 enrolled

Gynecologic

Neoplasms, Endometrial Neoplasms

NCT05317858 2026-04-16

LIMITLESS

30 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT05335811 2026-04-16

First-in-Human Assessment of Safety, Biodistribution and Pharmacokinetics of 18F-Fluoro-1-Naphthol (18F-4FN) for PET Imaging

55 enrolled

Endocrine Gland Neoplasms

NCT05398861 2026-04-16

Utidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of HER-2 Negative Advanced Breast Cancer

79 enrolled

Breast

HER-2 Negative Breast Cancer

NCT05475925 2026-04-16

A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

DermatologicLymphoidOther hematologic neoplasm

200 enrolled

Subcutaneous panniculitis-like T-cell lymphoma, Leukemia, Lymphoma, Leukemia, Large Granular Lymphocytic, Lymphoma, Extranodal NK-T-Cell, Enteropathy-Associated T-Cell Lymphoma

NCT05534438 2026-04-16

A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer

46 enrolled

Breast

Breast Neoplasms

NCT05537896 2026-04-16

Prospective Evaluation of Xerava Prophylaxis in Hematological Malignancy Patients With Prolonged Neutropenia

55 enrolled

Neutropenia, Hematologic Neoplasms

NCT05552755 2026-04-16

TUPELO

67 enrolled

Gastrointestinal

Adenomatous Polyposis Coli

NCT05554133 2026-04-16

Precision Optical Guidance for Oral Biopsy

90 enrolled

Oral Lesions

NCT05554393 2026-04-16

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

153 enrolled

Leukemia, Myeloid, Acute

NCT05564377 2026-04-16

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

2,900 enrolled

Gynecologic

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

NCT05580562 2026-04-16

ACTION

510 enrolled

Glioma

NCT05588141 2026-04-16

A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations

96 enrolled